- Home
- IMAB vs KMDA Comparison
IMAB vs KMDA Comparison
Compare IMAB & KMDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMAB
- KMDA
- Stock Information
- Founded
- IMAB 2014
- KMDA 1990
- Country
- IMAB United States
- KMDA Israel
- Employees
- IMAB N/A
- KMDA N/A
- Industry
- IMAB Biotechnology: Pharmaceutical Preparations
- KMDA Biotechnology: Pharmaceutical Preparations
- Sector
- IMAB Health Care
- KMDA Health Care
- Exchange
- IMAB Nasdaq
- KMDA Nasdaq
- Market Cap
- IMAB 384.6M
- KMDA 410.6M
- IPO Year
- IMAB 2020
- KMDA N/A
- Fundamental
- Price
- IMAB $4.38
- KMDA $7.14
- Analyst Decision
- IMAB Strong Buy
- KMDA Strong Buy
- Analyst Count
- IMAB 4
- KMDA 2
- Target Price
- IMAB $6.75
- KMDA $13.00
- AVG Volume (30 Days)
- IMAB 2.1M
- KMDA 51.8K
- Earning Date
- IMAB 11-02-2025
- KMDA 08-13-2025
- Dividend Yield
- IMAB N/A
- KMDA 2.80%
- EPS Growth
- IMAB N/A
- KMDA 27.97
- EPS
- IMAB N/A
- KMDA 0.32
- Revenue
- IMAB N/A
- KMDA $169,517,000.00
- Revenue This Year
- IMAB N/A
- KMDA $14.49
- Revenue Next Year
- IMAB N/A
- KMDA $10.12
- P/E Ratio
- IMAB N/A
- KMDA $21.69
- Revenue Growth
- IMAB N/A
- KMDA 9.67
- 52 Week Low
- IMAB $0.60
- KMDA $5.17
- 52 Week High
- IMAB $5.90
- KMDA $9.16
- Technical
- Relative Strength Index (RSI)
- IMAB 54.65
- KMDA 48.75
- Support Level
- IMAB $4.17
- KMDA $6.90
- Resistance Level
- IMAB $4.69
- KMDA $7.11
- Average True Range (ATR)
- IMAB 0.53
- KMDA 0.19
- MACD
- IMAB -0.12
- KMDA 0.01
- Stochastic Oscillator
- IMAB 25.44
- KMDA 45.28
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.